Search by Drug Name or NDC
NDC 33342-0004-25 Nevirapine 200 mg/1 Details
Nevirapine 200 mg/1
Nevirapine is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Macleods Pharmaceuticals Limited. The primary component is NEVIRAPINE.
MedlinePlus Drug Summary
Nevirapine is used along with other medications to treat human immunodeficiency virus (HIV) infection in adults and children 15 days of age and older. Nevirapine should not be used to treat healthcare workers or other individuals exposed to HIV infection after contact with HIV-contaminated blood, tissues, or other body fluids. Nevirapine is in a class of medications called non-nucleoside reverse transcriptase inhibitors (NNRTIs). It works by decreasing the amount of HIV in the blood. Although nevirapine does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other life-style changes may decrease the risk of transmitting (spreading) the HIV virus to other people.
Related Packages: 33342-0004-25Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Nevirapine
Product Information
| NDC | 33342-0004 |
|---|---|
| Product ID | 33342-004_99d52ed2-f3e5-476a-8ba6-ed2cee3aae8a |
| Associated GPIs | 12109050000320 |
| GCN Sequence Number | 027467 |
| GCN Sequence Number Description | nevirapine TABLET 200 MG ORAL |
| HIC3 | W5K |
| HIC3 Description | ANTIVIRALS, HIV-SPECIFIC, NON-NUCLEOSIDE, RTI |
| GCN | 31420 |
| HICL Sequence Number | 011592 |
| HICL Sequence Number Description | NEVIRAPINE |
| Brand/Generic | Generic |
| Proprietary Name | Nevirapine |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Nevirapine |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 200 |
| Active Ingredient Units | mg/1 |
| Substance Name | NEVIRAPINE |
| Labeler Name | Macleods Pharmaceuticals Limited |
| Pharmaceutical Class | Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 3A Inducers [MoA], Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Non-Nucleoside Analog [EXT], Non-Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA090688 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 33342-0004-25 (33342000425)
| NDC Package Code | 33342-004-25 |
|---|---|
| Billing NDC | 33342000425 |
| Package | 12 BLISTER PACK in 1 CARTON (33342-004-25) / 10 TABLET in 1 BLISTER PACK |
| Marketing Start Date | 2019-01-28 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |